The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
Articles
[키워드] 95% CI
All participant
B.1.1.7 variant
BNT162b2
BNT162b2 vaccine
Cellular immune response
cellular response
clinical effectiveness
Cohort
cohort study
consecutive patient
Control
controls
Coverage
COVID-19 vaccine
COVID-19 vaccine trials
defined
determine
Diagnosis
Dilution
East
eligible
England
evaluate
evaluated
extended interval
females
finding
first dose
foundation
funding
groups
healthy control
healthy controls
humoral
Humoral immunity
IL-17
IL-2
IL-21
IL-23
immune response
Immune-mediated inflammatory disease
immunogenicity
Immunosuppressant
Immunosuppression
individual
inhibitors
inhibitory
interferon-γ
IQR
London
lowest
males
median
median age
methotrexate
monotherapy
Necrosis
neutralising antibody response
Neutralising titre
NHS
of BNT162b2
participant
Participants
Patient
Pfizer-BioNTech
preserved
Primary outcome
receive
receiving
recruited
Seven
significantly lower
single dose
South
spike glycoprotein
spike-specific T-cell response
study population
the healthy
the SARS-CoV-2
therapeutic
Therapies
Thoma
TNF
Trust
vaccination
vaccine immunogenicity
Volunteer
were excluded
white
wild-type SARS-CoV-2
[DOI] 10.1016/S2665-9913(21)00212-5 PMC 바로가기 [Article Type] Articles
[DOI] 10.1016/S2665-9913(21)00212-5 PMC 바로가기 [Article Type] Articles